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MaBACKGROUND Identiﬁcation of novel biomarkers is needed to improve the diagnosis and prognosis of heart failure
(HF). Metabolic disturbance is remarkable in patients with HF.
OBJECTIVES This study sought to assess the diagnostic and prognostic values of metabolomics in HF.
METHODS Mass spectrometry–based proﬁling of plasma metabolites was performed in 515 participants; the discovery
phase study enrolled 51 normal control subjects and 183 HF patients, and the validation study enrolled 63 control
subjects and 218 patients with stage C HF. Another independent group of 32 patients with stage C HF who recovered to
New York Heart Association functional class I at 6 and 12 months was proﬁled as the “recovery” group.
RESULTS A panel of metabolites, including histidine, phenylalanine, spermidine, and phosphatidylcholine C34:4, has a
diagnostic value similar to B-type natriuretic peptide (BNP). In the recovery group, the values of this panel signiﬁcantly
improved at 6 and 12 months. To evaluate the prognostic values, events were deﬁned as the combined endpoints of
death or HF-related re-hospitalization. A metabolite panel, which consisted of the asymmetric methylarginine/arginine
ratio, butyrylcarnitine, spermidine, and the total amount of essential amino acids, provided signiﬁcant prognostic values
(p < 0.0001) independent of BNP and traditional risk factors. The prognostic value of the metabolite panel was better
than that of BNP (area under the curve of 0.85 vs. 0.74 for BNP) and Kaplan-Meier curves (log rank: 17.5 vs. 9.95). These
ﬁndings were corroborated in the validation study.
CONCLUSIONS Metabolomics demonstrate powerful diagnostic value in estimating HF-related metabolic distur-
bance. The proﬁle of metabolites provides better prognostic value versus conventional biomarkers. (J Am Coll Cardiol
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ABBR EV I A T I ON S
AND ACRONYMS
ACC = American College of
Cardiology
AHA = American Heart
Association
AUC = areas under the curve
BNP = B-type natriuretic
peptide
HF = heart failure
NO = nitric oxide
OPLS-DA = orthogonal-
projection-to-latent-structure–
discriminant-analysis
VIP = variable importance in
the projection
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1510effectiveness of current treatments for late-
stage HF necessitates novel interventional
measures to curb maladaptive molecular
processes and avoid the progression of HF
to advanced stages.
A variety of HF biomarkers have been
identiﬁed, with B-type natriuretic peptide
(BNP) and the N-terminal fragment of the
proprotein, emerging as clinically useful
markers for the diagnosis and prognosis of HF
(2,3). Natriuretic peptides also have prog-
nostic value for individuals atmoderate risk of
cardiovascular disease without overt symp-
toms (4). Unfortunately, these biomarkers
do not provide additional information on
molecular targets for therapeutic interven-tions. In addition, application of a single biomarker
may be insufﬁcient for evaluating patients with HF; a
combination of multiple molecules may be better for
such an evaluation.SEE PAGE 1521The etiology of a substantial proportion of HF pa-
tients remains unexplained according to the current
knowledge of cardiovascular risk factors. Regardless
of the heterogeneous etiologies, HF development is
causally related to the heart’s inability to meet the
metabolic demands of the body. The accompanying
changes in global metabolism—sometimes referred to
as a “metabolic storm”—suggest a clinical application
of an HF-speciﬁc metabolome for diagnostic and
prognostic purposes. The current staging of HF is on
the basis of the consensus developed by the American
College of Cardiology (ACC) and the American Heart
Association (AHA), instead of pathogenic mechanisms
(5). Taking advantage of the high throughput and the
potential of developing multiple biomarkers, metab-
olomics is a platform for identifying metabolic sig-
natures in patients with pre-HF to those with
advanced HF, independent of traditional risk factors.
A thorough understanding of HF-associated meta-
bolic perturbation, together with advances in nutri-
genomic research, might permit the development of
personalized preventive measures.
Previously, on the basis of analysis of urine sam-
ples from a limited number of patients, Kang et al. (6)
showed that concentrations of 1-methylnicotinamide,
2-oxoglutarate, and pyruvate were lower in pa-
tients with ischemic HF, but that concentrations of
acetate, ketone bodies, cytosine, methylmalonate,
and phenylacetylglycine were all higher. Another
study identiﬁed pseudouridine and 2-oxoglutarate as
2 biomarkers of HF (7). In the present study, we
recruited more HF patients and examined the clinicalapplicability and signiﬁcance of plasma metabolomic
analysis in the diagnosis and prognosis of HF. We also
sought to determine whether metabolomic analysis
provides sensitive evaluation of HF at different
stages and in disease regression after therapeutic
interventions.
METHODS
PATIENTS AND STUDY DESIGN. For the discovery
phase study, patients at HF stages B and C were
enrolled from January 2011 to December 2012. Pa-
tients at stage A HF and normal control subjects were
then enrolled from October 2011 to December 2012.
HF stages A, B, and C were classiﬁed according to the
ACC/AHA HF classiﬁcation system (5). Stage C pa-
tients were those hospitalized due to acute or
decompensated chronic HF and ages 20 to 85 years.
Exclusion criteria included the following: 1) the
presence of systemic disease, such as hypothyroid-
ism, decompensated liver cirrhosis, and systemic
lupus erythematosus; 2) the presence of disorders
other than HF that might compromise 6-month sur-
vival; 3) patients who were bedridden for >3 months
and/or unable to stand alone; 4) patients with a serum
creatinine of >3 mg/dl; and 5) patients with severe
coronary artery disease without complete revascu-
larization therapy. Informed consent was obtained
from all patients. The study was designed and carried
out in accordance with the principles of the Declara-
tion of Helsinki and with approval from the Ethics
Review Board of Chang Gung Memorial Hospital.
The validation phase study set was composed of
another independent population that included 63
normal control subjects and 218 patients at stage C HF
who were recruited from July 2011 to May 2013.
(Online Figure 1 depicts the study ﬂow).
UNTARGETED METABOLIC ANALYSIS. Liquid chro-
matographic separation for processed plasma was
achieved on a 100  2.1 mm Acquity 1.7-mm C8 column
(Waters Corp., Milford, Massachusetts) using an
ACQUITY TM UPLC system (Waters Corp.). The eluent
was analyzed via high-deﬁnition, time-of-ﬂight mass
spectrometry (MS) (SYNAPT G1, Waters Corp.) oper-
ating in electrospray ionization-positive ion mode.
Raw mass spectrometric data were processed using
MassLynx V4.1 and MarkerLynx software (Waters
Corp.). The multivariate data matrix was analyzed by
SIMCA-P software (version 13.0, Umetrics AB, Umea,
Sweden).
STATISTICAL ANALYSES. Results are expressed as
the mean  SD for continuous variables and as the
number (percent) for categorical variables. Data were
compared by 2-sample or paired Student’s t tests,
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appropriate. Metabolomics analysis was performed
using several software programs. Data import and
pre-processing steps for targeted MS data were
done using TargetLynx (Waters Corp.). The integrated
MetIDQ software (Biocrates, Innsbruck, Austria)
was applied to streamline data analysis by auto-
mated calculation of metabolite concentrations. To
maximize identiﬁcation of differences in metabolic
proﬁles between groups, the orthogonal-projection-
to-latent-structure–discriminant-analysis (OPLS-DA)
model was applied using the SIMCA-P software
(version 13.0, Umetrics AB). The variable importance
in the projection (VIP) value of each variable in the
model was calculated to indicate its contribution
to the classiﬁcation. A higher VIP value represented
a stronger contribution to discrimination among
groups. VIP values >1.0 were considered signiﬁcantly
different. Logistic regression analysis was used for
diagnosis of HF. Odds ratios and 95% conﬁdence
intervals were calculated.
Follow-up data were collected as scheduled or at
the last available visit. Cox proportional hazard
models were used to determine independent pre-
dictors of the ﬁrst deﬁned events (death or HF-related
re-hospitalization) after controlling for covariates.
Hazard ratios and 95% conﬁdence intervals were also
calculated. All statistical analyses were 2-sided and
performed using SPSS software (version 15.0, SPSS,
Chicago, Illinois). A p value of <0.05 was considered
signiﬁcant.
Detailed methods are provided in the Online
Appendix.
RESULTS
A total of 515 participants included 114 normal control
subjects and 401 patients. The discovery phase in-
cluded 234 participants, including 51 normal control
subjects and 183 HF patients at stages A (n ¼ 43), B
(n ¼ 67), and C (n ¼ 73) (Online Figure 1). Baseline
characteristics and laboratory data are shown in
Table 1. A signiﬁcant trend of changes was noted in
most of the variables for the normal control subjects
to patients at HF stages A, B, and C. Compared with
the normal control subjects, stage C patients had
remarkably higher BNP levels and a wider QRS com-
plex, but they also had lower levels of total choles-
terol, low- and high-density lipoprotein cholesterol,
sodium, hemoglobin, albumin, and in the estimated
glomerular ﬁltration rate. Although there were no
signiﬁcant differences in age among the patient
groups, HF patients were older than the normal con-
trol subjects. In addition, the percent of men washigher in the patient groups. Coronary artery disease
was the major HF etiology for study patients. The
validation phase study included 63 normal control
subjects and 218 stage C HF patients; the related de-
mographic characteristic data are shown in Online
Table 1.
Initially, for the untargeted metabolomics analysis,
119 plasma samples, from 51 normal control subjects
and 68 stage C HF patients from the 234 discovery
phase participants, were examined (Online Figure 1).
In the metabolomic proﬁling, 897 positive-mode fea-
tures were identiﬁed and applied for SIMCA-P anal-
ysis. The OPLS-DA score plot and loading plot showed
remarkable separation between the control subjects
and stage C HF patients (Online Figure 2). The results
of untargeted analysis revealed amino acids and
phospholipids to be important discriminators be-
tween the normal control subjects and stage C HF
patients. Therefore, stable isotope dilution-multiple
reaction monitoring MS was performed in all 234
participants to quantify amino acids, biogenic
amines, acylcarnitines, and phospholipids in both the
discovery phase and validation groups.
To test whether metabolites could discriminate pa-
tients from control subjects, plasma from 51 normal
control subjects and from 73 stage C HF patients in
the discovery phase study were subject to targeted
metabolite analysis, and datasets were analyzed by the
OPLS-DA model. The OPLS-DA score plots demon-
strated considerable separation between the normal
control subjects and the stage C HF patients in the ﬁrst
principal component (Figure 1A; x-axis, called t[1]),
which probably reﬂected the HF-related pathological
variations between the subjects. The metabolites res-
ponsible for the discrimination between these 2 groups
(those with VIP >1.5) are listed in Table 2 and Online
Table 2. This model (i.e., the “training set”) was then
used to estimate HF status in the following analyses.
The calculated value of this model is called tPS[1].
Figure 1B is the score plot of data corresponding to
the age-matched control subjects (n ¼ 51) and stage C
HF patients (n ¼ 50) in the discovery phase study,
whose demographic characteristic data are shown in
Online Table 3. The distribution of the data in the
score plots was similar to that shown in Figure 1A,
suggesting that discrimination of the 2 groups was
independent of age. On the basis of this training set,
patients at stage A (n ¼ 43) and stage B (n ¼ 67) were
calculated by tPS[1] (Figures 1C and 1D, respectively).
The score plots of stage B patients showed that the
data spanned the regions over the stage C HF patients
and the normal control subjects, suggesting the het-
erogeneity of stage B as deﬁned by the AHA/ACC
criteria.
TABLE 1 Patient Characteristics in the Discovery Phase Study
Control Subjects
(n ¼ 51)
Stage A
(n ¼ 43)
Stage B
(n ¼ 67)
Stage C
(n ¼ 73) p Value for Trend
Age, yrs 55.2  4.4 60.1  10.8 59.9  12.8 64.1  12.8 <0.001
Male 19 (37.3) 35 (81.4) 57 (85.1) 41 (56.2) 0.073
LVEF 72.3  8.0 70.1  8.9 50.5  14.1 37.2  15.6 <0.001
Blood pressure, mm Hg
Systolic 125.7  15.7 124.3  16.8 123.4  19.9 124.7  19.7 0.742
Diastolic 75.6  12.1 76.7  11.8 77.1  12.8 72.0  12.5 0.156
Heart rate, beats/min 72.3  11.3 76.7  11.3 73.6  9.2 79.5  14.1 0.006
Comorbidity
Diabetes mellitus 0 (0) 18 (41.9) 22 (32.8) 38 (52.1) <0.001
Chronic kidney disease 0 (0) 11 (25.6) 16 (23.9) 27 (37) <0.001
Hypertension 0 (0) 31 (72.1) 48 (71.6) 54 (74.0) <0.001
Atrial ﬁbrillation 0 (0.) 3 (7.0) 7 (10.4) 21 (28.8) <0.001
COPD 0 (0) 3 (7.0) 2 (3.0) 12 (16.4) 0.002
Ischemic 0 (0) 31 (72.1) 59 (88.1) 44 (60.3) <0.001
Body mass index, kg/m2 24.4  3.3 26.1  4.2 25.8  4.3 24.9  4.6 0.601
Medication
ACEI or ARB 0 (0) 15 (34.9) 48 (71.6) 62 (84.9) <0.001
Beta-blocker 0 (0) 18 (41.9) 53 (79.1) 51 (69.9) <0.001
Digoxin 0 (0) 0 (0) 5 (7.5) 21 (28.8) <0.001
Diuretic agent 0 (0) 4 (9.3) 15 (22.4) 49 (67.1) <0.001
Statins 0 (0) 21 (48.8) 40 (59.7) 27 (37.0) <0.001
Fenoﬁbrate 0 (0) 4 (9.3) 1 (1.5) 0 (0) 0.325
Statins/fenoﬁbrate 0 (0) 23 (53.5) 41 (61.2) 27 (37.0) <0.001
OHA/insulin 0 (0) 15 (34.9) 21 (31.3) 29 (39.7) <0.001
Laboratory data
BNP, pg/ml 9.2  8.8 43.0  69.4 209.2  359.7 851.6  793.8 <0.001
Log (BNP) 0.88  0.23 1.34  0.49 1.94  0.60 2.71  0.52 <0.001
Cholesterol, mg/dl 214.7  35.5 175.1  43.0 182.3  41.9 169.2  58.6 <0.001
Triglyceride, mg/dl 99.2  55.9 186.3  110.3 138.4  100.6 120.2  68.6 0.762
LDL-C, mg/dl 139.2  30.1 104.3  37.8 112.9  39.8 108.1  52.1 0.001
HDL-C, mg/dl 55.3  12.9 39.5  11.3 42.2  13.3 38.6  17.8 <0.001
Serum sodium, mEq/l 140.4  1.3 138.5  3.0 139.3  2.2 138.6  4.1 0.006
Hemoglobin, g/dl 13.9  1.2 13.9  1.6 13.8  1.9 12.6  2.1 <0.001
Total bilirubin, mg/dl 0.8  0.3 0.8  0.3 0.8  0.4 1.1  0.6 0.001
Albumin, g/dl 4.4  0.2 4.1  0.3 3.9  0.3 3.5  0.6 <0.001
Hemoglobin A1c, % 5.7  0.3 6.6  1.4 6.5  1.4 6.7  1.5 <0.001
eGFR, ml/min/1.73 m2* 99.1  19.2 78.6  24.6 79.7  32.2 65.6  27.9 <0.001
QRS complex, ms 89.6  8.6 94.3  15.6 96.9  19.4 106.3  24.9 <0.001
Values are mean  SD or n (%). *Chronic kidney disease ¼ eGFR <60 ml/min/1.73 m2.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BNP ¼ B-type natriuretic peptide; COPD ¼ chronic obstructive pulmonary disease;
eGFR ¼ estimated glomerular ﬁltration rate; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; LVEF ¼ left ventricular ejection
fraction; OHA ¼ oral hypoglycemic agents.
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and normal control subjects (diagnostic value), the
receiver-operating characteristic curves were plotted
for both BNP and t[1] (by taking all metabolites into
the principal component analysis) (Figure 1E). The
areas under the curves (AUCs) were 0.99 and 1.0,
respectively. Notably, there were 4 important me-
tabolites that signiﬁcantly contributed to the diag-
nostic value for HF, namely, histidine, phenylalanine,
spermidine, and phosphatidylcholine C34:4 (once
known as “lecithin”) (Table 3). These 4 metabolites
gave rise to an AUC of 0.99, which was better thanthat of each metabolite alone (Figure 1E). On the basis
of the training set composed of these 4 metabolites,
the score plot (tPS[2]) distribution of the normal
control subjects and the stage C HF patients are
shown in Figure 1F. The odds ratio of the BNP and
tPS[2] levels for identifying stage C HF (vs. normal
control subjects) are presented in Table 3. The diag-
nostic value of tPS[2] was independent of diabetes
mellitus and other comorbidities. The targeted quan-
titative analysis of the validation set revealed similar
diagnostic levels for the 4-metabolite panel as observed
in the discovery samples (Table 3, Online Table 4).
FIGURE 1 Diagnostic Values of Metabolomics for Heart Failure
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metabolite concentrations by liquid chromatography tandem mass spectrometry. (A) OPLS-DA score plots show the considerable separation
between 51 normal control subjects and 73 stage C HF patients. This model (the “training set”) was then used to calculate tPS[1] of patients at
different stages of HF. (B) The OPLS-DA score plots of age-matched stage C patients (n ¼ 50) and normal control subjects (n ¼ 51). (C and D)
The OPLS-DA score plots of patients at stages A and B, respectively. The ellipse shown in the model represents the Hotelling T-square test with
95% conﬁdence. (E) The ROC curves for the diagnosis of HF by B-type natriuretic peptide (BNP), tPS[1], and tPS[2]. (F) The OPLS-DA score
plots represent the tPS[2] values calculated by combining 4 important metabolites. OPLS-DA ¼ orthogonal-projection-to-latent-structure–
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TABLE 2 Statistical Analysis of Targeted Metabolites* Between Control Subjects and Stage C Heart Failure Patients in the
Discovery Phase Study
Metabolite, mM VIP Score
Control Subjects
(n ¼ 51)
Stage C
(n ¼ 73) p Value
Histidine 2.47 99.3  18.0 77.7  18.4 <0.001
Phenylalanine 2.29 57.4  8.9 76.9  22.6 <0.001
Ornithine/arginine 2.27 1.02  0.23 2.11  1.32 <0.001
Phosphatidylcholine diacyl C34:4 2.26 0.97  0.36 0.59  0.35 <0.001
Ornithine 2.13 56.9  18.7 84.0  32.5 <0.001
Phosphatidylcholine diacyl C36:2 2.12 226.4  58.4 172.9  52.4 <0.001
Octadecadienyl carnitine 1.99 0.053  0.034 0.105  0.070 <0.001
Phosphatidylcholine diacyl C36:1 1.98 44.8  11.1 35.3  10.2 <0.001
Log (glutamate) 1.95 1.28  1.03 1.68  1.12 <0.001
Phosphatidylcholine diacyl C36:0 1.89 4.98  1.16 3.85  1.43 <0.001
Spermidine 1.87 0.25  0.03 0.37  0.17 <0.001
Log (spermine) 1.84 –0.93  0.21 –0.63  0.39 <0.001
Phosphatidylcholine diacyl C40:5 1.83 9.32  3.25 6.97  2.60 <0.001
Phosphatidylcholine diacyl C36:6 1.83 0.91  0.46 0.56  0.39 <0.001
Phosphatidylcholine diacyl C33:3 1.80 0.23  0.06 0.17  0.07 <0.001
Citrulline/Ornithine 1.79 1.16  0.73 0.67  0.51 <0.001
Phosphatidylcholine diacyl C38:5 1.77 44.2  12.6 33.6  14.0 <0.001
Creatinine 1.72 103.9  41.6 185.3  135.5 <0.001
Phosphatidylcholine diacyl C36:3 1.69 94.0  21.5 78.1  21.1 <0.001
Sphingomyelin C20:2 1.68 1.12  0.29 0.87  0.35 <0.001
Phosphatidylcholine diacyl C38:3 1.68 31.1  8.5 24.9  8.2 <0.001
Phosphatidylcholine acyl-alkyl C38:6 1.65 7.10  2.28 5.52  2.14 <0.001
Putrescine/ornithine 1.64 0.008  0.005 0.005  0.003 0.001
Phosphatidylcholine acyl-alkyl C34:2 1.64 8.30  2.46 6.56  2.37 <0.001
Aromatic amino acids 1.62 163.9  24.6 193.3  49.8 <0.001
Hydroxybutyrylcarnitine 1.61 0.030  0.015 0.049  0.032 <0.001
Phosphatidylcholine diacyl C40:4 1.61 2.76  0.83 2.22  0.71 <0.001
Phosphatidylcholine acyl-alkyl C36:2 1.57 9.79  2.23 8.09  2.63 <0.001
Hexose 1.57 5,285  1,986 6,993  2,814 <0.001
Phosphatidylcholine acyl-alkyl C36:3 1.56 6.4  1.8 5.2  1.7 <0.001
Octadecenoylcarnitine 1.54 0.12  0.07 0.18  0.10 <0.001
Butrylcarnitine 1.52 0.23  0.06 0.35  0.23 <0.001
Values are mean  SD. *Includes metabolites with a VIP score >1.5.
VIP ¼ variable importance in the projection.
TABLE 3 Univariable and Multivariable Analyses of the Associations of BNP and Metabolites With Heart Failure Diagnosis
Discovery Phase Validation
Odds Ratio 95% CI p Value Odds Ratio 95% CI p Value
Univariable analysis
Log (BNP) ( 10–2) 1.09 1.03–1.14 0.001 1.04 1.03–1.06 <0.0001
Histidine, mM 0.93 0.91–0.96 <0.0001 0.88 0.84–0.92 <0.0001
Phenylalanine, mM 1.11 1.06–1.16 <0.0001 1.20 1.12–1.26 <0.0001
PC aa C34:4, mM  10–1 0.76 0.67–0.85 <0.0001 0.78 0.71–0.85 <0.0001
Spermidine, mM  10–1 6.64 2.98–14.79 <0.0001 22.74 6.94–74.49 <0.0001
tPS[2] (4 metabolites: histidine, phenylalanine,
PC aa C34:4, spermidine) ( 10–1)
2.72 1.44–5.14 <0.0001 2.71 2.09–3.50 <0.0001
Multivariable analysis*
Log (BNP) ( 10–2) 1.16 1.01–1.34 0.048 1.08 1.03–1.12 <0.0001
tPS[2] (4 metabolites: histidine, phenylalanine,
PC aa C34:4, spermidine) ( 10–1)
4.19 1.23–14.34 0.02 2.88 2.01–4.13 <0.0001
The range of tPS[2], values calculated by the combination of 4 metabolites, is from –2.5 to 2.65 (on the basis of logistic regression model). *Multivariable analysis adjusting
for age, sex, diabetes mellitus, chronic kidney disease, and hypertension.
CI ¼ conﬁdence interval; PC aa ¼ phosphatidylcholines diacyl; other abbreviations as in Table 1.
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1515The metabolites that changed at different stages
are shown in Table 2 and Online Table 2. These
metabolites included amino acids, biogenic amines,
and phospholipids. Compared with the control sub-
jects, several plasma metabolites related to argi-
nine metabolism, such as glutamine and citrulline,
were lowered in stage C HF patients, but levels
of glutamate, ornithine, spermine, and spermidine
were elevated. Aromatic amino acids, such as tyro-
sine and phenylalanine, were elevated in stage
C HF patients, although levels of several phospha-
tidylcholines were decreased, whereas taurine was
increased. The metabolites with signiﬁcant changes
were mapped onto 7 biochemical pathways (Central
Illustration).
To estimate the prognostic value of metabolomics
and BNP, the following analyses focused on HF pa-
tients at stages B and C (n ¼ 140). During a follow-up
of 1.3  0.8 years, there were 18 all-cause deaths and
29 HF-related re-hospitalizations. To identify any
potential metabolic predictors of a composite of
all-cause death and HF-related re-hospitalization,
extensive analyses on the whole metabolite dataset
were conducted. A combination of 4 metabolite
components (dimethylarginine/arginine ratio, sper-
midine, butyrylcarnitine, and total essential amino
acid amount) gave rise to an optimal prognostic value
that was remarkably better than BNP. The tPS[3] was
calculated from these 4 metabolite components and
the AUCs of receiver-operating characteristics curves
for tPS[3], tPS[1], and BNP levels were 85%, 78%, and
74%, respectively (Figure 2A). Table 4 and Online
Table 5 show the Cox univariable and multivariable
analyses for these parameters on the prognosis. The
prognostic value of tPS[3] was still highly signiﬁcant
even after adjusting for BNP levels, age, left ventric-
ular ejection fraction, diabetes mellitus, chronic kid-
ney disease, and hypertension. The validation study
reconﬁrmed these ﬁndings (Table 4, Online Table 5,
Figure 2D).
The mean of tPS[3] (2.9, range 0.04 to 5.63) was set
as the cutoff value for the prognostic prediction. In
Figure 2B, the Kaplan-Meier curves revealed that a
tPS[3] of $2.9 at pre-discharge was associated with
a higher composite of HF-related re-hospitalization
and all-cause death (log rank ¼ 17.5; p < 0.0001 ). In
comparison, the Kaplan-Meier curves of patients
categorized according to BNP (cutoff value set at 350
pg/ml) (8) are shown in Figure 2C (log rank ¼ 9.9;
p ¼ 0.002). The targeted quantitative analysis for the
4 metabolite components of the validation phase set
revealed better prognostic levels than BNP than
that observed in the discovery samples (Figures 2D
to 2F).The correlation between tPS[2] and BNP levels was
modest (r ¼ 0.53; p < 0.001) (Figure 3A). To verify the
diagnostic value of tPS[2], metabolomics analysis,
together with BNP measurement, was also performed
in 32 patients (22 men and 10 women; age 54 
11 years) who were recruited earlier than this
study’s enrollment period. These patients, named the
“recovery” group, were initially hospitalized due to
acute or decompensated chronic HF, but then they
improved to New York Heart Association functional
class I and survived for >1 year. Plasma was analyzed
before discharge and again at 6 and 12 months post-
discharge. The serial changes in tPS[2] and BNP
values are shown in Figure 3B. The tPS[2] values for
the 32 patients at pre-discharge stage were signiﬁ-
cantly higher than those of the normal control sub-
jects (p < 0.001). Compared with pre-discharge levels,
both the values of tPS[2] and BNP remarkably
decreased at 6 months and remained steady at 12
months after discharge (p < 0.001).
DISCUSSION
In the present study, we demonstrated that metab-
olomics is a promising tool for the diagnosis and
prognosis of HF. Plasma concentrations of metabo-
lites, such as histidine, phenylalanine, ornithine,
spermine, spermidine, phosphatidylcholines, and
taurine, show signiﬁcant differences among patients
at different stages of HF. Combinations of metabolites
are as good as the conventional biomarker BNP for
diagnosis and better than BNP for prognosis. The
value of estimating metabolic proﬁles in HF is far
beyond diagnosis only, as demonstrated in the vali-
dation study. In contrast, the common changes in
plasma metabolites identiﬁed in HF patients with
different etiologies suggest that HF development may
involve a universal metabolic disturbance related
to HF-associated dysfunction in multiple organs
(9). A number of pathways, namely, the glutamate-
ornithine-proline pathway, polyamine synthesis,
and phosphatidylcholines synthesis, may be spe-
ciﬁcally affected during HF progression (Central
Illustration).
The key metabolites that show signiﬁcant differ-
ences in abundance between stages C and A HF,
between stage C HF and normal control subjects, and
between the acute phase and 6 or 12 months later
in the recovery group are histidine, phenylalanine,
spermidine, and phosphatidylcholine C34:4. These
metabolites are mapped to biochemical pathways
(Central Illustration). Anomalous ﬂuxes through these
metabolic pathways may show the interplay be-
tween metabolism in multiple tissues and organs and
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(Top) The proposed scheme indicates that the decrease in cardiac output leads to disturbances of the metabolic pathways and the appearance of speciﬁc metabolites in
the circulation of heart failure (HF) patients. These metabolites probably serve as biomarkers for HF. (Bottom) Disturbances occur in the following metabolic pathways:
(a) urea cycle, (b) biopterin cycle, (c) MTA/methionine cycle, (d) ornithine-proline-glutamate, (e) polyamine synthesis, (f) methylation (phosphatidylcholine), and
(g) transsulfuration (taurine) in HF patients. Metabolites marked in salmon, blue, black, and gray indicate metabolites, the abundance of which signiﬁcantly increased,
signiﬁcantly decreased, remained unchanged, and were not measured, respectively. a-KG ¼ alpha-ketoglutarate; BH4 ¼ tetrahydrobiopterin; GAA ¼ guanidinoacetate;
Hcy ¼ homocysteine; MTA ¼ 5-methylthioadenosine; NO ¼ nitric oxide; PE ¼ phosphatidylethanolamine; SAM ¼ S-adenosylmethionine.
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TABLE 4 Univariable Analysis on Prognostic Value in HF Patients
Discovery Phase Validation
HR 95% CI p Value HR 95% CI p Value
Log (BNP) ( 10–1) 1.12 1.06–1.21 0.003 1.06 1.01–1.12 0.034
t[1] ( 10–1) 1.86 1.30–2.65 0.001
tPS[2] ( 10–1) 1.98 1.43–2.74 <0.0001
Total DMA/arginine ratio, mM 1.85 1.49–2.29 <0.0001 1.42 1.05–1.94 0.02
Spermidine, mM  10–1 1.32 1.03–1.69 0.02 2.38 1.22–4.76 0.01
C4, mM 1.36 1.08–1.71 0.01 6.23 2.51–15.49 <0.0001
Total essential amino acids (mM) 0.66 0.45–0.97 0.03 0.93 0.91–0.94 0.001
tPS[3] (4 metabolites: total DMA/
arginine ratio, spermidine, C4,
total essential amino acids) ( 10–1)
2.78 2.04–3.78 <0.0001 3.08 2.19–4.33 <0.0001
The ranges of t[1] and tPS[2] are from –2.64 to 2.5 and from –2.5 to 2.65, respectively. The ranges of tPS[3]s are from 0.04 to 5.6 and from 1.2 to 6.3 for the discovery phase
and validation studies, respectively (on the basis of regression models).
C4 ¼ butyrylcarnitine; DMA ¼ dimethylarginine; HR ¼ hazard ratio; t[1] ¼ values calculated by all metabolomics analysis; tPS[2] ¼ values calculated by 4 metabolites for
diagnosis; other abbreviations as in Tables 1 and 3.
FIGURE 2 Prognostic Values of Metabolomics
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FIGURE 3 Serial Follow-Up After Acute HF
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together with the impact of systemic congestion.
Plasma metabolomics represent the metabolic view of
the so-called cardio–hepatic interaction, cardiorenal
syndrome, and catabolic status in the muscular sys-
tem. Keeping in line with the main ﬁndings,
levels of histidine and phosphatidylcholine C34:4
increased, whereas levels of phenylalanine and sper-
midine decreased in patients whose medical condi-
tion improved.
Application of tracer-based metabolic ﬂux analysis
on patients is associated with technical feasibility and
ethical issues. Despite the lack of ﬂux analysis, our
metabolomics data still provided an excellent account
of metabolic changes in patients.
Mitochondrial dysfunction and a shift from fatty
acid to glucose utilization for energy production
are the main metabolic changes seen in the failing
heart. Histidine, which is capable of being converted
to glutamate, enters the glutamate-ornithine-proline
pathway or Krebs cycle as alpha-ketoglutarate, which
supplies ornithine and energy for cardiac tissues.
Glucose can be converted to phosphoribosyl pyro-
phosphate, which is essential to histidine biosyn-
thesis. Over-consumption of glucose as an energy
source may impair the cellular ability to replenish
histidine deﬁciency, which is probably caused
by inadequate intake. Uncoupling of nitric oxidesynthase may involve the pathogenesis of HF (10).
Induction of nitric oxide synthase-2 and concurrent
tetrahydrobiopterin depletion in the myocardium
contribute to HF in animal models and human
subjects (10,11). Consistent with such notions, accu-
mulation of phenylalanine and tyrosine in HF
patients during progression from stage A to C HF
are indicative of tetrahydrobiopterin depletion. This
occurs in parallel with a signiﬁcant decrease in
arginine levels, which may disturb nitric oxide (NO)
production and lead to cardiac dysfunction (12). In
contrast, the increased phenylalanine and tyrosine
levels may also be associated with the accumula-
tion of aromatic amino acids caused by increased
muscular protein breakdown and impaired liver
function.
Our study showed the stage-speciﬁc elevation of
plasma polyamine metabolites, namely, spermidine
and spermine. The polyamine and NO pathways
are inter-regulated in several experimental models.
NO inhibits ornithine decarboxylase and polyamines
production (13,14). Ornithine, the upstream precursor
to polyamines formation, can be produced from
arginine by arginase or by arginine:glycine amidino-
transferase. The decrease in arginine and the accu-
mulation of ornithine in stage C HF patients may
be associated with impaired NO synthesis and
enhanced polyamine synthesis. The ornithine level
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tional urea cycle in the liver. The involvement of
polyamines in the pathogenesis of cardiac diseases
is not unprecedented. Polyamines increase in car-
diac tissue after ascending aortic stenosis and in
various models of experimentally-induced cardiac
hypertrophy (15,16). Moreover, spermidine has been
shown to be detrimental to cardiomyocytes under
hypoxic stress (17).
Reduction in plasma levels of most phosphatidyl-
cholines in HF patients is intriguing. Previous studies
reported alteration of lipid homeostasis, including
changes in metabolism of phosphatidylcholines, in
associated cardiomyopathies (18,19). Disturbances in
the ratio of phosphatidylcholine to phosphatidyl-
ethanolamine and anomalies in membrane phos-
pholipid homeostasis alter the membrane-associated
protein complexes interactions that regulate myo-
cardial metabolism and cell signaling (20). In con-
trast, because the liver plays a major role in
phosphatidylcholine metabolism and lipoprotein
secretion, anomalous phosphatidylcholine meta-
bolism may be associated with abnormal hepatic
functions in the failing heart (21). A congested liver is
common in patients with congestive HF; it remains
to be elucidated whether abnormal liver function
plays an active role in HF pathogenesis or the
liver merely responds passively to the remarkably
increased metabolic input from nonhepatic tissues
and organs.
Plasma metabolome is indicative of HF-associated
global changes in metabolism rather than that of the
heart alone, and likely involves interactions between
various tissues and organs. As shown in our study,
the limited correlation between BNP and tPS[2] sug-
gests either novel HF-related metabolic pathways or
general markers of poor status. Previous studies
identiﬁed a few speciﬁc metabolic proﬁles of liver
dysfunction, including elevated bile acids and
decreased lysophosphatidylcholines and a decreased
Fischer ratio, which is the molar ratio of plasma
branched chain amino acids levels to aromatic amino
acids levels (22).
Although some of these changes were also noted in
our patients (Online Table 2), the main metabolic
proﬁle discovered in our study is distinct. Meta-
bolic signatures are different between HF and
non-HF cachexia. Cachexia related to chronic lung
disease and cancer, for example, has been asso-
ciated with increases in very low- and low-density
lipoproteins (23), glutamine, aspartate, arginine, and
asparagine, as well as decreases in aminoadipate,
beta-aminoisobutyrate, and 1-methylhistidine (24).
Comparison of these reports and our ﬁndings suggestthat the metabolic proﬁles described in our study
are speciﬁc to HF. However, the speciﬁcity of our
proﬁles for both diagnostic and prognostic values
needs to be assessed in patients with non-HF diseases
or dyspnea. In contrast, the same AUCs of BNP and
tPS[2] suggest that metabolomics is highly valuable
for evaluating HF-related metabolic disturbances. It
opens a new avenue for assessing patient response to
nutritional interventions.
Our metabolomic ﬁndings demonstrate impor-
tant clinical applications beyond diagnosis. Another
metabolite set consisting of 4 metabolite components
provides a better prognostic value than the conven-
tional biomarker, BNP. This metabolic proﬁle covers
different aspects of pathogenesis. For instance, the
total dimethylarginine/arginine ratio is indicative of
endothelial dysfunction (25), spermidine is probably
indicative of rescuing compensation or toxicity to
cardiomyocytes, butyrylcarnitine is indicative of
anomalous lipid and energy metabolism, and total
essential amino acids is indicative of malnutrition.
These ﬁndings raise the possibility of adjunctive
nutritional therapy to improve the prognosis of pa-
tients with severe HF.
STUDY LIMITATIONS. Because systemic and myo-
cardial metabolism can shift rapidly in response
to HF-related pathophysiology and stress, the pre-
sent study did not address the changes in patient
metabolic proﬁles at different time points within a
short period after hospital discharge. For better data
interpretation and clinical applications in the future,
the dynamics and stability of metabolomic proﬁles
need to be established.
CONCLUSIONS
HF is associated with a variety of abnormalities in
multiple metabolic pathways and subsequent occur-
rence of a complex “metabolic storm.” Apart from the
understanding of pathogenesis, the proﬁle of metab-
olites provides a more sensitive and better evaluation
for HF staging than that deﬁned by current classiﬁ-
cation schemes, paving the way for monitoring the
outcome of therapeutic interventions.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Plasma biomarkers that identify abnormalities of cardiac
metabolism in patients with HF have prognostic value
beyond that of natriuretic peptide levels or conventional
clinical risk factors.
TRANSLATIONAL OUTLOOK: Additional clinical
studies are needed to examine the effects of nutritional
and other interventions that target speciﬁc cardiac
metabolic disturbances on clinical outcomes in patients
with HF and their correlations with plasma levels of
metabolic biomarkers.
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